Genmab A/S (OTCMKTS:GNMSF) Short Interest Up 47.6% in January

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a large increase in short interest in January. As of January 30th, there was short interest totaling 89,880 shares, an increase of 47.6% from the January 15th total of 60,883 shares. Based on an average daily volume of 106 shares, the short-interest ratio is presently 847.9 days. Approximately 0.1% of the company’s stock are short sold. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 106 shares, the short-interest ratio is presently 847.9 days.

Genmab A/S Stock Performance

Shares of GNMSF opened at $300.00 on Friday. The stock’s 50-day moving average is $326.19 and its two-hundred day moving average is $297.24. Genmab A/S has a 12 month low of $170.00 and a 12 month high of $352.00.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.